Background:Endocrine therapies are accompanied by side effects that significantly impact the quality of life (QoL) of women with breast cancer. Adequate diet is important for fulfilling nutritional requirements, preserving health, and supporting therapy in this vulnerable population.Methods: This preliminary study evaluated the QoL of life and dietary intake in 185 women with breast cancer on two therapies, aromatase inhibitors (AIs) and tamoxifen, using the Functional Assessment of Cancer Therapy—Endocrine Symptoms (FACT-ES), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and Breast Cancer Specific Questionnaire (QLQ-BR23) and a 24 h dietary recall. A total of 185 women were included in the study and fulfilled the FACT-ES, of whom 73 fulfilled other two questionnaires and a 24 h recall.Results: No significant differences were found in the overall QoL between groups. Joint pain (95.3%) and reduced libido (84.7%) were most common with AIs, while tamoxifen users more frequently reported weight gain and irritability (93.0%, each), and vasomotor and gynecological symptoms. Macronutrient intake was similar, though AIs users consumed more energy-dense (p≤ 0.001) and sugary foods (p= 0.034), while tamoxifen users had higher omega-6 PUFA intake. Both groups exhibited suboptimal intake of vitamin D, calcium, and selenium, and a higher phosphorus consumption relative to recommended daily values.Conclusions: Preliminary findings showed that QoL and dietary intake were comparable between patients with BC on AIs and tamoxifen treatment. Endocrine-related symptoms were more prevalent among tamoxifen users, whereas joint pain was most common in AIs users. Nutritional interventions may be warranted in both groups to ensure adequate intake of essential micronutrients in accordance with recommended dietary guidelines.
背景：内分泌治疗伴随的副作用显著影响乳腺癌患者的生活质量。对于这一脆弱人群，合理饮食对满足营养需求、维持健康及支持治疗至关重要。 方法：本初步研究采用癌症治疗功能评估-内分泌症状量表、欧洲癌症研究与治疗组织生活质量核心问卷及乳腺癌特异性问卷，结合24小时膳食回顾法，评估了185例接受芳香化酶抑制剂与他莫昔芬治疗的乳腺癌患者的生活质量与膳食摄入情况。所有入组患者均完成内分泌症状量表评估，其中73例同时完成其余两份问卷及膳食回顾。 结果：两组患者总体生活质量未见显著差异。芳香化酶抑制剂组最常见关节疼痛（95.3%）与性欲减退（84.7%），而他莫昔芬组更常报告体重增加与易怒症状（各93.0%），以及血管舒缩症状与妇科症状。宏量营养素摄入量相近，但芳香化酶抑制剂组摄入更多高能量食物与含糖食品，他莫昔芬组则摄入更多ω-6多不饱和脂肪酸。两组患者均存在维生素D、钙、硒摄入不足，且磷摄入量高于推荐日摄入值。 结论：初步研究显示，接受芳香化酶抑制剂与他莫昔芬治疗的乳腺癌患者在生活质量与膳食摄入方面具有相似性。他莫昔芬组内分泌相关症状更为普遍，而芳香化酶抑制剂组关节疼痛最为常见。两组患者均需营养干预以确保必需微量营养素摄入符合膳食指南推荐标准。
肿瘤(癌症)患者之家